Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | WDR5 | P61964 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.50 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.49 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31317828 | 1.00 | POLB (0.57) | POLBPFKFB3MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3558954 | 0.87 | MEP1B (0.46) | POLBPFKFB3MAPT | |
| SCHEMBL6291394 | 0.85 | POLB (0.52) | POLBPFKFB3MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31317790 | 0.84 | POLB (0.70) | POLBPFKFB3MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4191490 | 0.84 | POLB (0.70) | POLBPFKFB3MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL25111766 | 0.84 | MAP1LC3B (0.53) | POLBMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL29522198 | 0.81 | ALDH1A1 (0.75) | POLBPFKFB3MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1677059 | 0.81 | ALDH1A1 (0.75) | POLBPFKFB3MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3555821 | 0.81 | PARP1 (0.45) | KMT2A | |
| SCHEMBL3552908 | 0.81 | CA1 (0.46) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190176081-A1 | GAS SEPARATION MEMBRANE, GAS SEPARATION MODULE, GAS SEPARATION DEVICE, GAS SEPARATION METHOD, AND POLYIMIDE COMPOUND | FUJIFILM CORPORATION (JP) | 2019-06-13 | — | — | US | disclosed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| EP-1651640-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651641-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009994-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | POLB 1310/4885PFKFB3 466/4885MAPT 3157/4885 |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | POLB 1018/4885PFKFB3 1474/4885MAPT 3551/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | POLB 1310/4885PFKFB3 466/4885MAPT 3157/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | POLB 1310/4885PFKFB3 466/4885MAPT 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.